Immunotherapies targeting various immune checkpoints, including programmed death 1 (PD‐1), programmed death‐ligand 1 (PD‐L1), Cytotoxic T‐Lymphocyte Antigen 4 (CTLA4) and programmed cell death 1 ligand 2 (PD‐L2), have a beneficial impact on NSCLC.7, 8, 9. The gene discussed is PDCD1LG2; the disease is non-small cell lung carcinoma.